Breaking News
August 21, 2018 - Clinical Trials Balance Out Urban, Rural Cancer Survival Rates
August 21, 2018 - New target found for treating thoracic aortic aneurysm
August 21, 2018 - Tumor cells’ ‘tells’ may allow some cancer patients to dodge unnecessary chemotherapy
August 21, 2018 - Dehydration changes shape and activity of the brain, reduces task performance
August 21, 2018 - Scientists discover peptides that can be used as new antibiotic candidates
August 21, 2018 - ‘Compulsivity circuit’ may drive alcohol-seeking behavior in heavy drinkers
August 21, 2018 - Type 2 diabetes on the rise among youngsters
August 21, 2018 - Genital warts may promote HIV sexual transmission
August 21, 2018 - Drop the C-word to reduce anxiety and overtreatment, say experts
August 21, 2018 - Kid-friendly MRI equipment has advantages for grown-ups, too
August 21, 2018 - Scleroderma Foundation names Tulane professor as ‘Doctor of the Year’
August 21, 2018 - Chagas disease causes chronic heart disease and has spread outside of Latin America
August 21, 2018 - FDA stirs debate by approving ‘natural’ app
August 21, 2018 - Clay may help fight disease-causing bacteria in wounds
August 21, 2018 - Emerging field of diabetology could address growing crisis in health care
August 21, 2018 - Experts examine stool protein biomarkers that indicate inflammatory bowel disease
August 21, 2018 - Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
August 21, 2018 - Ovarian cancer cells hoard iron to fuel growth
August 21, 2018 - New Biodesign fellows will focus on vision care
August 21, 2018 - Prenatal DDT Exposure Associated with Greater Risk of Autism
August 21, 2018 - Cruciferous vegetables found to protect against colon cancer in mice
August 21, 2018 - New studies point to a promising future for bioengineered teeth
August 21, 2018 - ACR expresses concerns on step therapy in a recent meeting with HSS Secretary
August 21, 2018 - Gene therapy with telomerase does not increase cancer risk, study shows
August 21, 2018 - Ovarian cancer screening influenced by unconscious bias, study shows
August 21, 2018 - Scientists report novel gene therapy that halts vision loss in canine model of blinding disease
August 21, 2018 - RxBenefits introduces new tailored and flexible approach to managing hospital pharmacy benefits
August 21, 2018 - Motif Bio Announces FDA Acceptance of New Drug Application With Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
August 21, 2018 - Google Glass helps kids with autism read facial expressions, study finds
August 21, 2018 - Thrombospondin-1 contributes to development of aortic aneurysm in mice and humans, study finds
August 21, 2018 - National Foundation for Cancer Research receives Safeway Foundation grant
August 21, 2018 - Protein aggregation in neurons linked to gene regulation in Huntington’s disease
August 21, 2018 - Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA
August 21, 2018 - FDA Approves Opdivo (nivolumab) for Certain Patients with Previously Treated Small Cell Lung Cancer
August 21, 2018 - Success of blood test for autism affirmed
August 21, 2018 - Diabetic patients with disrupted sleep may need more time to heal their wounds
August 21, 2018 - AADE honors six educators for achievements in diabetes education
August 21, 2018 - Scientists find two molecules that may combat cancer and chronic infections
August 21, 2018 - Two Strategies for Preventing Diabetes in Minority Patients
August 21, 2018 - Living as a Gallbladder Cancer Survivor
August 21, 2018 - Can we predict the long-term outcome of boys with ADHD?
August 21, 2018 - GBCA creates model for developing scientist-advocate collaborations in cancer research
August 21, 2018 - Healthy diet could help promote healthy cellular aging in women
August 21, 2018 - Researchers develop gene expression predictor for immunotherapy response in melanoma
August 21, 2018 - Genome sequences of ape parasites provide insights on origin and early evolution of malaria
August 21, 2018 - MDI Biological Laboratory introduces Morris Scientific Discovery Fund for eligible research programs
August 21, 2018 - Pediatric brain tumor patients who undergo radiation less likely to recall recently experienced events
August 21, 2018 - Micro-flow model reveals complex interactions between the brain’s blood vessels and nerve cells
August 21, 2018 - Study investigates impact of osteoporosis on risk of developing dementia
August 21, 2018 - Federal method fails to detect most stores that sell cigarettes to minors
August 21, 2018 - Workers in open office seating have less stress than those in private offices and cubicles
August 21, 2018 - 1 in 4 in U.S. Has a Disability, CDC Reports
August 21, 2018 - Studies provide new insights into the role of sleep in chronic pain
August 21, 2018 - Study shows that rogue proteins may underlie some ALS and frontotemporal dementia cases
August 21, 2018 - Elevated LDL cholesterol levels linked to higher risk of CVD death in young, healthy people
August 21, 2018 - Measles cases on the rise in Europe
August 21, 2018 - CURE Media Group welcomes CancerCare to Strategic Alliance Partnership Program
August 21, 2018 - Blood management program associated with fewer transfusions in orthopedic patients
August 21, 2018 - Researchers create the world’s first artificial retina
August 21, 2018 - Yale researchers identify racial disparities in prescribing opioids for chronic pain
August 21, 2018 - BOOST-3 clinical trial aims to improve outcomes for severe TBI patients
August 21, 2018 - New study highlights Alzheimer’s herpes link, experts say
August 21, 2018 - Airline crew don’t have significantly elevated risk of thyroid cancer, new study finds
August 21, 2018 - States leverage federal funds to help insurers lower premiums
August 21, 2018 - New badge course explores research around skeletal muscle as an endocrine organ
August 21, 2018 - TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis
August 21, 2018 - Increased levels of human herpesvirus ID’d in Alzheimer’s
August 21, 2018 - To help patients quash pain, researcher develops practical guide for health care providers
August 20, 2018 - Medicine on the front line to be presented at Medical Innovation 2018
August 20, 2018 - Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody
August 20, 2018 - The man who sold America on vitamin D — and profited in the process
August 20, 2018 - Finding the light in antimicrobials
August 20, 2018 - Unique pain program helps surgical patients wean off opioids safely and effectively
August 20, 2018 - Strawberries could mitigate colonic inflammation
August 20, 2018 - FDA Accepts New Drug Application (NDA) to Review Midazolam Nasal Spray, an Investigational Product for the Acute Treatment of Seizure Clusters
August 20, 2018 - Using Facebook to help young adults quit smoking
August 20, 2018 - ‘Liquid biopsy’ predicts lymphoma therapy success within days | News Center
August 20, 2018 - 5 Questions with Jordan Orange, Chair of Pediatrics
August 20, 2018 - New assay may help improve both sarcoma diagnosis and treatment
August 20, 2018 - New information on the brain regions related to metacognition, tactile sense
New Models May Predict Progression in Early dcSSc

New Models May Predict Progression in Early dcSSc

image_pdfDownload PDFimage_print

Action Points

  • In early diffuse cutaneous systemic sclerosis (dcSSc), patients with shorter disease duration and less skin thickening were more likely to experience disease progression, and positivity for anti-RNA polymerase III (Pol3) indicated patients more likely to progress.
  • Note that researchers have not externally validated their predictive models based on skin thickening, disease duration and Pol3 positivity, and that will be an important step before they are used widely.

Two prediction models that may identify progression in early diffuse cutaneous systemic sclerosis (dcSSc) have been developed for clinical practice and randomized controlled trials, researchers reported.

The first predictive model, which included skin thickening measured by the modified Rodnan skin score (mRSS), disease duration, and the interaction between the two, had an accuracy of 60.9%, an area under the curve (AUC) of 0.666 and a positive predictive value (PPV) of 33.8%. By adding a variable for anti-RNA polymerase III (Pol3) positivity, the model reached an accuracy of 71%, AUC of 0.711, and PPV of 41%, according to Ariane L. Herrick, MD, of the University of Manchester in England, and colleagues.

“Among patients with early dcSSc, those with shorter disease duration and lower mRSS are most likely to be ‘progressors’ with a trade-off between the two factors and patients who are Pol3+ have the highest mRSS peaks and tend to reach peak mRSS earliest, providing a valuable message for clinicians that patients with short disease duration and Pol3+ must be especially closely monitored,” they wrote in the Annals of the Rheumatic Diseases.

While the model incorporating Pol3 more accurately identified high-risk patients, it may be too restrictive, they noted, adding that “both models were more flexible (for a given skin score) and more accurate than a ’22 mRSS’ cut-off model and may offer advantages for cohort enrichment in clinical trials to ensure that the most informative patients are included.”

Patients with dcSSc have high morbidity and mortality, which is associated with the degree of severity of skin fibrosis and thickening measured by the mRSS. The mRSS gauges skin thickness at 17 sites on a scale of 0 to 3, for a maximum score of 51. The skin score tends to progress rapidly in the first 3 to 5 years of dcSSc, then plateau and fall.

In the prospective European Scleroderma Observational Study (ESOS), researchers studied 326 adult patients with early dcSSc from 50 centers and 19 countries. Of the total sample, 65 patients started on methotrexate, 118 on mycophenolate mofetil, 87 on cyclophosphamide, and 56 had no immunosuppressant.

The primary outcome measure was the mRSS, which was recorded every 3 months. Because progression status did not significantly differ among treatment groups, the researchers analyzed mRSS trajectories regardless of treatment protocol. “Progressors” were defined as patients who experienced a 5-unit and 25% increase in mRSS over 12 months (±3 months).

In the study, 22.5% of early dcSSc patients progressed and 77.5% did not. Progression status could not be assessed in 33 patients.

At baseline, progressors had shorter disease duration (median 8.1 vs 12.6 months, P=0.001) and lower mRSS (median 19 vs 21 units, P=0.030) than nonprogressors.

Pol3+ patients had higher skin scores at baseline than patients in other autoantibody groups (P=0.003), despite similar disease durations (P=0.593). They seemed more likely to progress than other groups: 29.2% of Pol3+ patients were progressors, compared with 11.9% in the no-autoantibody group (P=0.105). Pol3+ patients had the highest peaks of all autoantibody groups, with a median peak of 35 units (P=0.001).

As a single predictor for progression, mRSS performed poorly with an AUC of 0.588. Duration of skin thickening performed better, with an AUC of 0.634. A model that combined mRSS, disease duration and the interaction between the two improved those univariate performances, with an AUC of 0.666. That model, known as model A, had 73.4% sensitivity, 57.2% specificity, and accurately predicted 60.9% of cases.

Adding an indicator variable for Pol3 positivity (model B) improved results. This yielded an AUC of 0.711, 60.4% sensitivity, 74.2% specificity, and accurately predicted 71% of cases.

“The key finding here was the development of a predictive model for mRSS (disease) progression which had an accuracy of 60.9%, achieved by recognizing that the initial skin score is a poor predictor of progression on its own and that prediction is improved by simultaneously accounting for disease duration,” the authors wrote. “By including autoantibodies in this analysis, the model improved and reached an accuracy of 71.0%.”

Model A can help inform randomized controlled trials, they noted, while model B can help identify patients at higher risk for progression in clinical settings. Using model B to inform patient selection into clinical trials may be too restrictive and could produce a sample that does not reflect the overall dcSSc population, they cautioned.

They added that by measuring skin scores every 3 months, they were able to capture peaks in mRSS that might not have been seen otherwise. “Had we only recorded baseline and 12-month data (two observations), 53% of our cases of progression would have been missed,” they wrote.

The study has several limitations, including the fact that, for some patients, peak mRSS may have occurred before they entered the study. Among patients whose progression status was unknown, 36.4% died, which might have induced bias.

Also, the researchers have not externally validated their models, adding that this will be an important step before they are used widely.

ESOS was funded by a grant from the European League Against Rheumatism Orphan Disease Programme, and Scleroderma, and Raynaud’s U.K.

Herrick and co-authors disclosed relationships with Actelion, Apricus, BMS, Celgene, Bayer, Boehringer Ingelheim, JB Therapeutics, Sanofi-Aventis, Novartis, Array BioPharma, Active Biotech, Galapagos, Medac, Pfizer, Anamar RuiYi, 4D Science, Biogenidec, BMS, EpiPharm, Ergonex, espeRare Foundation, Genentech/Roche, GSK, Inventiva, Lilly, Medac, Medimmune, Pharmacyclics, Serodapharm, Sinoxa ,UCB, Richter Gedeon, Inventiva, and Merck-Serono.

2018-01-15T09:30:00-0500

Tagged with:

About author

Related Articles